Arnold Suhr Netherlands B.V. has been acquired by Active Capital Company
The private shareholders of Arnold Suhr Netherlands B.V. have sold the company to Active Capital Company (ACC).
Founded in 1947, Arnold Suhr is a specialty distributor of ingredients, including quinine, iodine and sports nutrition. The company has a top-3 position in each of its key markets. Its customers include major soft drink producers and pharmaceutical companies. Arnold Suhr has a number of strategic investments together with its suppliers, with joint ventures across the world. The company is headquartered in the Netherlands and has a sales office in China. Arnold Suhr has a yearly turnover of approximately US$40 million and 20 employees.
ACC is an Amsterdam-based independent hands-on private equity firm. ACC invests in companies in the Netherlands with revenues between US$5-80 million and is active in industrial goods and services and technical wholesale. Besides new capital, the firm brings in operational and financial expertise.
Oaklins’ team in the Netherlands acted as M&A advisor to the seller in this transaction.
Talk to the deal team
Related deals
Bluegem Capital Partners and AREV Partners have acquired 100% of Groupe Pinard
Bluegem Capital Partners and AREV Partners have successfully completed the acquisition of the prestigious Groupe Pinard from IK Partners.
Learn moreLumiforte partners with Kartesia to propel global growth and innovation
Lumiforte, a global leader in innovative smart coatings for greenhouse horticulture, sports line-marking and other functional coatings for agriculture and industry, is excited to announce an investment from Kartesia, a European specialist in capital solutions for small and medium-sized companies. Horticoop, a longstanding shareholder of Lumiforte and a key player in the horticultural industry through its investment cooperative, continues to remain a shareholder.
Learn morePanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production
PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.
Learn more